VenatoRx Pharmaceuticals Initiates Enrollment in Phase 3 Trial of Cefepime/VNRX-5133 in Patients with Complicated Urinary Tract Infections - Yahoo Finance
VenatoRx Pharmaceuticals Initiates Enrollment in Phase 3 Trial of Cefepime/VNRX-5133 in Patients with Complicated Urinary Tract Infections Yahoo Finance
Demonstrated potent activity against carbapenem-resistant Enterobacteriaceae and carbapenem-resistant Pseudomonas aeruginosa.
Comments
Post a Comment